Skip to main content
Journal cover image

Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF).

Publication ,  Journal Article
Kelly, JP; Mentz, RJ; Hasselblad, V; Ezekowitz, JA; Armstrong, PW; Zannad, F; Felker, GM; Califf, RM; O'Connor, CM; Hernandez, AF
Published in: Am Heart J
August 2015

BACKGROUND: Despite initial in-hospital treatment of acute heart failure (HF), some patients experience worsening HF (WHF). There are limited data about the outcomes and characteristics of patients who experience in-hospital WHF. METHODS AND RESULTS: We assessed the characteristics and outcomes of patients with and without WHF in the ASCEND-HF trial. Worsening HF was defined as at least 1 symptom or sign of new, persistent, or WHF requiring additional intravenous inotropic/vasodilator or mechanical therapy during index hospitalization. We assessed the relationship between WHF and 30-day mortality, 30-day mortality or HF hospitalization, and 180-day mortality. We also assessed whether there was a differential association between early (days 1-3) vs late (day ≥4) WHF and outcomes. Of 7,141 patients with acute HF, 354 (5%) experienced WHF. Patients with WHF were more often male and had a history of atrial fibrillation or diabetes, lower blood pressure, and higher creatinine. After risk adjustment, WHF was associated with increased 30-day mortality (odds ratio 13.37, 95% CI 9.85-18.14), 30-day mortality or HF rehospitalization (odds ratio 6.78, 95% CI 5.25-8.76), and 180-day mortality (hazard ratio 3.90, 95% CI 3.14-4.86) (all P values < .0001). There was no evidence of a difference in outcomes between early and late WHF (all P values for comparison ≥ .2). CONCLUSIONS: Worsening HF during index hospitalization was associated with worse 30- and 180-day outcomes. Worsening HF may represent an important patient-centered outcome in acute HF and a focus of future treatments.

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

August 2015

Volume

170

Issue

2

Start / End Page

298 / 305

Location

United States

Related Subject Headings

  • Ventricular Function, Left
  • Treatment Outcome
  • Time Factors
  • Survival Rate
  • North Carolina
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male
  • Injections, Intravenous
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kelly, J. P., Mentz, R. J., Hasselblad, V., Ezekowitz, J. A., Armstrong, P. W., Zannad, F., … Hernandez, A. F. (2015). Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). Am Heart J, 170(2), 298–305. https://doi.org/10.1016/j.ahj.2015.04.007
Kelly, Jacob P., Robert J. Mentz, Vic Hasselblad, Justin A. Ezekowitz, Paul W. Armstrong, Faiez Zannad, G Michael Felker, Robert M. Califf, Christopher M. O’Connor, and Adrian F. Hernandez. “Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF).Am Heart J 170, no. 2 (August 2015): 298–305. https://doi.org/10.1016/j.ahj.2015.04.007.
Kelly, Jacob P., et al. “Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF).Am Heart J, vol. 170, no. 2, Aug. 2015, pp. 298–305. Pubmed, doi:10.1016/j.ahj.2015.04.007.
Kelly JP, Mentz RJ, Hasselblad V, Ezekowitz JA, Armstrong PW, Zannad F, Felker GM, Califf RM, O’Connor CM, Hernandez AF. Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). Am Heart J. 2015 Aug;170(2):298–305.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

August 2015

Volume

170

Issue

2

Start / End Page

298 / 305

Location

United States

Related Subject Headings

  • Ventricular Function, Left
  • Treatment Outcome
  • Time Factors
  • Survival Rate
  • North Carolina
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male
  • Injections, Intravenous
  • Humans